THE TRUTH ABOUT: Melanoma - The Untold Story

Why Citi Is Sounding the Alarm on Moderna Stock

The cancer pipeline gave Moderna's shares a rocket boost. Citi, however, just checked the stock’s price tag and wasn’t exactly impressed.

Barchart · Oct 1

Opinion: The First Personalized mRNA Cancer Vaccine Just Passed a Major Test: Now Comes the Hard Part

A late-stage trial found that a custom-built mRNA therapy added to immunotherapy reduced melanoma recurrence. An oncologist argues the result is a genuine milestone, but patients deserve clear answers on the size of the benefit, survival, cost, and access before the hype takes over.

Medical Daily · Sep 23

5 Self-Examination Techniques That Catch Cancer and Skin Disease Early in Just Ten Minutes a Month

Why Your Hands Are the First Line of ScreeningA 2022 study published in The Lancet Oncology found that in low- and middle-income countries, a category India still partially occupies for cancer infrastructure, over 60 percent of breast cancer cases present at stage three or four. The gap between early and…

Times Life · Sep 10

Chilean Scientists Report Promising Results For Skin Cancer Vaccine

A Chilean clinical trial of TRIMELVax, a vaccine made with protein from the loco sea snail, shows encouraging signs against advanced melanoma.

Latin Times · Sep 2

No safe tan: Why Canada’s sunburn problem keeps getting worse

Scroll through social media and you will encounter a strange vocabulary for an old impulse: “tanmaxxing,” “UV chasing” and “SPF shunning.” In some corners of the internet, sunscreen is described as toxic, while a “natural” tan is portrayed as protective.

The Conversation · Aug 26

Moderna Added 45 Billion Dollars in a Day on a Melanoma Vaccine Result with No Effect Size Disclosed

Moderna and Merck's melanoma vaccine met its Phase 3 goals, but no effect size was released, and some analysts called the market reaction excessive.

Medical Daily · Aug 25

Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.

Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?

Barchart · Aug 21

Moderna’s 177% Surge Has Investors Asking What Comes Next

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.

MarketBeat · Aug 21

Moderna, Merck's Cancer Vaccine Breakthrough Raises Hope For New Wave Of Personalized Treatments

Moderna and Merck's experimental cancer vaccine has delivered positive results in a late-stage melanoma trial, giving a major boost to personalized mRNA treatments as rivals including BioNTech and Roche pursue similar approaches.

International Business Times · Aug 21

Moderna's Vaccine Breakthrough Supported by AI: Musk Praises mRNA Despite 'Obvious Misuse During COVID'

Moderna and Merck's personalised mRNA vaccine shows promising Phase 3 results in melanoma treatment, potentially revolutionising cancer care with tailored immunotherapy.

International Business Times UK · Aug 21